Live Feeds
● LIVE Updated 57m ago · 11 sources tracked

Leukemia vaccine passes key trial, adding to breakthrough year for cancer drugs

An experimental blood cancer immunotherapy developed by Sellas Life Sciences has successfully passed a key clinical trial, marking a significant milestone in a strong year for cancer drugs. The vaccine extended survival in patients with acute myeloid leukaemia, demonstrating a survival benefit of nine months in a late-stage study. Following the positive data, company shares surged and tripled in value. The treatment also reduced the overall risk of death in the clinical trial, adding strong momentum to the biotechnology sector and placing the developer among top industry performers.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (11)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ An experimental blood cancer immunotherapy developed by Sellas Life Sciences passed a key clinical trial.
  • ✓ The vaccine marked a nine-month survival benefit in late-stage study results.
  • ✓ Sellas Life Sciences stock tripled following the release of the cancer vaccine data.
🛡️ Source Corroboration: 11 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Sellas Life Sciences released clinical trial data showing its experimental blood cancer vaccine extended patient survival and reduced the risk of death.

Live updates

  1. Leukaemia Vaccine Passes Key Trial

    An experimental blood cancer immunotherapy developed by Sellas Life Sciences has successfully passed a key clinical trial, marking a significant milestone in a strong year for cancer drugs. The vaccine extended survival in patients with acute myeloid leukaemia, demonstrating a survival benefit of nine months in a late-stage study. Following the positive data, company shares surged and tripled in value. The treatment also reduced the overall risk of death in the clinical trial, adding strong momentum to the biotechnology sector and placing the developer among top industry performers.

    Why it matters

    Acute myeloid leukaemia is a severe form of blood cancer with limited treatment options, making late-stage trial successes rare and highly valuable. Immunotherapies that target specific cancer antigens have increasingly become a focal point of oncology research. The positive results from this late-stage study validate years of targeted investment in cancer vaccines and could open new pathways for treating blood-related malignancies.

    What is confirmed

    • An experimental blood cancer immunotherapy developed by Sellas Life Sciences passed a key clinical trial.
    • The vaccine marked a nine-month survival benefit in late-stage study results.
    • Sellas Life Sciences stock tripled following the release of the cancer vaccine data.

    What to watch next

    • Further peer-reviewed publication of the clinical trial data
    • Regulatory filings or discussions with health authorities regarding approval pathways
    Sources used for this update (11)
    1. kffhealthnews.org — KFF Health News
    2. aisignal.kr — 넷플릭스 — 최근 동향·주요 뉴스 정리 (10월 30일 기준)
    3. www.research.va.gov — VA Research News Briefs
    4. The Washington Post — Leukemia vaccine passes key trial, adding to breakthrough year for cancer drugs
    5. Memorial Sloan Kettering Cancer Center — Vaccine Improves Survival in People with Acute Myeloid Leukemia (AML)
    6. Yahoo Finance — SLS Joins MRNA And ANL In Biotech’s Top 3 This Year — Here’s How A Late-2025 Bet Could Grow 10x From Here
    7. Fierce Biotech — Sellas marks 9-month survival benefit in late-stage leukemia vaccine study
    8. Reuters — Sellas vaccine extends survival in blood cancer trial, shares surge
    9. STAT — Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial
    10. Bloomberg.com — Sellas Life Sciences Stock Triples After Cancer Vaccine Data
    11. substack.news-items.com — The Beating Heart. - Substack,News Items ,John Ellis
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community